Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin phase 3 study in adults with type 2 diabetes inadequately controlled on metformin
2013-003290-95Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ertugliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoint: Change in HbA1c from baseline to Week 26. Started Jan 2014; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-003290-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003290-95.